Selecta Biosciences Inc (NASDAQ:SELB) reached a new 52-week low during trading on Thursday . The stock traded as low as $10.26 and last traded at $11.20, with a volume of 11,806 shares. The stock had previously closed at $10.65.

Several research firms have recently commented on SELB. Needham & Company LLC began coverage on shares of Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $28.00 price objective for the company. Stifel Nicolaus began coverage on shares of Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $23.00 price objective for the company. Finally, Canaccord Genuity began coverage on shares of Selecta Biosciences in a research note on Monday, July 18th. They set a “buy” rating and a $20.00 price objective for the company.

The stock has a 50-day moving average of $13.05 and a 200 day moving average of $13.05.

In other Selecta Biosciences news, Director Amir Nashat bought 150,000 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,100,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Nanodimension Management Ltd bought 385,000 shares of the business’s stock in a transaction that occurred on Monday, June 27th. The shares were acquired at an average cost of $14.00 per share, for a total transaction of $5,390,000.00. The disclosure for this purchase can be found here.

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.